Equities

Abingdon Health PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ABDX:LSE

Abingdon Health PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)6.00
  • Today's Change0.00 / 0.00%
  • Shares traded142.81k
  • 1 Year change-20.00%
  • Beta-0.0817
Data delayed at least 20 minutes, as of Feb 13 2026 16:41 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Abingdon Health plc is an international lateral flow contract research (CRO) and contract development and manufacturing organization (CDMO). The Company is an international developer, manufacturer and distributor of effective rapid tests. Its CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Its CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, and others. Its Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests. The Abingdon Simply Test’s other selected self-test products, such as the saliva pregnancy test, Salistick, which is sold through international distributors and through other channels in the United Kingdom and Ireland, such as pharmacy chains.

  • Revenue in GBP (TTM)8.43m
  • Net income in GBP-3.42m
  • Incorporated2008
  • Employees121.00
  • Location
    Abingdon Health PLCYork Biotech Campus, Sand HuttonYORK YO41 1LZUnited KingdomGBR
  • Phone+44 190 440 6050
  • Fax+44 190 446 2122
  • Websitehttps://www.abingdonhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Surgical Innovations Group Plc11.92m-1.44m4.20m88.00--0.4903--0.3523-0.0015-0.00150.01280.00920.93142.914.72135,397.70-11.22-7.76-14.17-9.6027.8929.97-12.04-11.660.95248.460.0987---0.57432.16-281.73---8.28--
Feedback plc885.62k-7.32m4.71m28.00--0.7641--5.32-0.2618-0.26180.03090.14070.1174--9.8331,629.29-96.97-38.54-105.98-41.6587.9290.05-826.25-435.27----0.00---25.0514.50-121.85---1.14--
Cambridge Nutritional Sciences PLC8.06m1.37m4.76m84.003.500.43052.380.59050.00570.00570.03380.04650.61533.593.5795,940.4810.42-3.2211.69-3.6766.4458.8516.94-7.213.79--0.021---14.77-3.23577.44---29.24--
Proteome Sciences plc4.53m-3.33m6.17m36.00------1.36-0.0113-0.01130.0153-0.02910.50875.925.75125,750.00-37.44-8.02----17.4345.80-73.60-15.070.0774-2.512.26---2.800.9731-39.42--31.03--
Genincode PLC2.91m-4.97m8.10m36.00--1.16--2.78-0.0232-0.02320.01370.00930.656215.742.8780,944.45-111.87---164.53--53.02---170.49--2.73-10.960.0669--25.05--36.80------
Rua Life Sciences PLC5.17m-850.00k8.84m33.00--1.24--1.71-0.0137-0.01370.08320.11510.54591.186.23---9.18---10.42--77.10---16.82--3.87--0.0995--------------
Verici DX PLC1.40m-5.58m10.19m15.00--0.8984--7.27-0.023-0.0230.00580.00750.2298--1.6777,870.79-91.48---119.40--81.60---398.12------0.102--229.62--32.75------
Cellbxhealth PLC2.62m-15.78m11.96m119.00--0.2897--4.56-0.0489-0.04890.00810.03620.10280.59391.4622,050.42-61.80-41.90-72.78-46.8162.2718.55-601.37-1,051.132.63-470.570.2387--30.92--29.34------
Genedrive PLC954.00k-5.23m12.36m43.00--5.21--12.95-0.0093-0.00930.00170.00230.1984--1.8022,186.05-108.81-77.52-153.92-106.30-----548.32-1,016.121.64--0.00--90.42-2.0726.06---10.48--
Abingdon Health PLC8.43m-3.42m15.06m121.00--2.19--1.79-0.0176-0.01760.04350.02741.179.713.8769,661.16-47.42-54.04-70.70-85.9144.3230.37-40.51-110.071.58--0.1625--37.399.99-168.69---26.92--
Inspiration Healthcare Group PLC45.20m-11.44m17.48m214.00--1.07--0.3868-0.1275-0.12750.50380.18261.032.005.91211,215.00-25.96-6.05-33.03-7.4544.3946.62-25.32-7.011.112.420.441--1.6516.56-148.04--39.05--
Renalytix PLC2.20m-14.95m17.99m45.00------8.18-0.0596-0.05960.008-0.01550.45477.644.54---309.18-83.70---107.2540.0028.27-680.00-1,519.311.17-24.576.38--31.06--55.14------
Aptamer Group PLC1.20m-2.42m23.60m31.00--12.61--19.62-0.0014-0.00140.00070.00070.42946.274.3538,806.45-86.53---154.00--48.13---201.50--1.48-84.630.2622--39.88--18.05------
Data as of Feb 13 2026. Currency figures normalised to Abingdon Health PLC's reporting currency: UK Pound GBX

Institutional shareholders

31.63%Per cent of shares held by top holders
HolderShares% Held
Canaccord Genuity Wealth Ltd.as of 31 Oct 202543.70m17.41%
Octopus Investments Ltd.as of 30 Sep 202519.61m7.81%
Rathbones Investment Management Ltd.as of 30 Sep 202513.94m5.55%
Unicorn Asset Management Ltd.as of 31 Jan 20261.93m0.77%
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025250.98k0.10%
More ▼
Data from 31 Oct 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.